Congdon N. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–85.

Article  PubMed  Google Scholar 

Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209–13.

Article  PubMed  Google Scholar 

Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia-Pac J Ophthalmol. 2017;6:493–7.

Google Scholar 

Barash A, Chui TYP, Garcia P, Rosen RB. Acute macular and peripapillary angiographic changes with intravitreal injections. Retina. 2020;40:648–56.

Article  PubMed  Google Scholar 

Abedi G, Adelman RA, Salim S. Incidence and management of elevated intraocular pressure with anti-vascular endothelial growth factor agents. Sem Ophthalmol. 2013;28:126–30.

Article  Google Scholar 

Achiron A. Intraocular pressure spikes following neodymium-doped yttrium aluminum garnet laser capsulotomy: Current prevalence and management in Israel. J Curr Glaucoma Pract. 2017;11:63–6.

Article  PubMed  PubMed Central  Google Scholar 

Baek SK, Kim JH, Kim JW, Kim CG. Increase in the population of patients with neovascular age-related macular degeneration who underwent long-term active treatment. Sci Rep. 2019;9:1–10.

Article  Google Scholar 

Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-vegf agents: what is the evidence? Retina. 2015;35:841–58.

Article  PubMed  Google Scholar 

Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32:1295–301.

Article  PubMed  Google Scholar 

Kim D, Nam WH, Kim HK, Yi K. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure? J Glaucoma. 2014;23:446–8.

Article  PubMed  Google Scholar 

Nariani A, Williams B, Hariprasad S. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Indian J Ophthalmol. 2016;64:643–7.

Article  PubMed  PubMed Central  Google Scholar 

Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology. 2015;122:1802–10.

Article  PubMed  Google Scholar 

Gabrielle P-H, Nguyen V, Wolff B, Essex R, Young S, Hunt A, et al. Intraocular pressure changes and vascular endothelial growth factor inhibitor use in various retinal diseases: long-term outcomes in routine clinical practice: data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2020;4:861–70.

Article  PubMed  Google Scholar 

Maruyama-Inoue M, Inoue T, Mohamed S, Kitajima Y, Ikeda S, Ito A, et al. Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration. Sci Rep. 2021;11:1–5.

Article  Google Scholar 

Novais EA, Baumal CR, Sarraf D, Freund KB, Duker JS. Multimodal imaging in retinal disease: a consensus definition. Ophthalmic Surg Lasers Imaging Retina. 2016;47:201–6.

Article  PubMed  Google Scholar 

Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014;158:313–27.

Article  Google Scholar 

Rusu I, Deobhakta A, Yoon D, Lee M, Slakter J, Klancnik J, et al. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments. Retina. 2014;34:2161–6.

Article  PubMed  Google Scholar 

Ramsey DJ, McCullum JC, Steinberger EE. Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022;36:1813–9.

Article  PubMed  Google Scholar 

Stein JD, Kim DS, Niziol LM, Talwar N, Nan B, Musch DC, et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011;118:1031–7.

Article  PubMed  Google Scholar 

Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.

Article  PubMed  Google Scholar 

Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye (Basingstoke). 2018;32:1010–20.

Google Scholar 

Van Bergen T, Jonckx B, Hollanders K, Sijnave D, Van de Velde S, Vandewalle E, et al. Inhibition of placental growth factor improves surgical outcome of glaucoma surgery. J Cell Mol Med. 2013;17:1632–43.

Article  PubMed  PubMed Central  Google Scholar 

Van Bergen T, Etienne I, Cunningham F, Moons L, Schlingemann RO, Feyen JHM, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 2019;69:116–36.

Article  PubMed  Google Scholar 

Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda D, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.

Article  PubMed  PubMed Central  Google Scholar